Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On January 13, 2026, Plus Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriti
Other Events. On January 14, 2026, the Company issued a press release announcing the pricing of the Offering, a copy of which is attached hereto as Exhibit 99.1
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 1.1 Underwriting Agreement, by and between the Company and Lake Street Capital Market